ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

Volume: 22, Issue: 12, Pages: 725 - 744
Published: Dec 1, 2020
Abstract
ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G protein coupled receptor (GPCR) dopamine receptor D2 (DRD2), and as an allosteric agonist of mitochondrial protease caseinolytic protease P (ClpP). Downstream of target engagement, ONC201 activates the ATF4/CHOP-mediated integrated stress response leading to TRAIL/Death Receptor 5...
Paper Details
Title
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
Published Date
Dec 1, 2020
Journal
Volume
22
Issue
12
Pages
725 - 744
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.